International Stem Cell (ISCO) Income from Continuing Operations (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Income from Continuing Operations of 203000.0 for Q4 2025, down 1791.67% year-over-year from 12000.0 in Q4 2024, and up 51.78% quarter-over-quarter from 421000.0 in Q3 2025.
International Stem Cell (ISCO) Income from Continuing Operations (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Income from Continuing Operations for 16 consecutive years, with 203000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 1791.67% year-over-year to 203000.0; the TTM figure through Dec 2025 stood at 2009000.0 (down 127.78% YoY), while the FY2025 annual figure was 7912000.0, down 3.76% from the prior year.
- Income from Continuing Operations improved to 203000.0 in Q4 2025 per ISCO's latest filing, from 421000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 160000.0 in Q4 2022 and bottomed at 937000.0 in Q3 2021.
- Historically, Income from Continuing Operations has averaged 336900.0 across 5 years, with a median of 294500.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 145.2% — and 2023, when it tumbled 8850.0%.
- International Stem Cell's Income from Continuing Operations stood at 354000.0 in 2021, then surged by 145.2% to 160000.0 in 2022, then plunged by 303.12% to 325000.0 in 2023, then jumped by 103.69% to 12000.0 in 2024, then slumped by 1791.67% to 203000.0 in 2025.
- Business Quant data shows ISCO's Income from Continuing Operations at 203000.0 in Q4 2025, 421000.0 in Q3 2025, and 450000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | -69,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -424,000.00 |
| Dec 31, 2025 | -203,000.00 |
| Sep 30, 2025 | -421,000.00 |
| Jun 30, 2025 | -450,000.00 |
| Mar 31, 2025 | -935,000.00 |
| Dec 31, 2024 | 12,000.00 |
| Sep 30, 2024 | -125,000.00 |
| Jun 30, 2024 | -505,000.00 |
| Mar 31, 2024 | -264,000.00 |
| Dec 31, 2023 | -325,000.00 |
| Sep 30, 2023 | -131,000.00 |
| Jun 30, 2023 | -179,000.00 |
| Mar 31, 2023 | -34,000.00 |
| Dec 31, 2022 | 160,000.00 |
| Sep 30, 2022 | -335,000.00 |
| Jun 30, 2022 | -2,000.00 |
| Mar 31, 2022 | -9,000.00 |
| Dec 31, 2021 | -354,000.00 |
| Sep 30, 2021 | -937,000.00 |
| Jun 30, 2021 | -901,000.00 |